NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $1.22 0.00 (0.00%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Connect Biopharma Stock (NASDAQ:CNTB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$1.16▼$1.2250-Day Range$1.00▼$1.6052-Week Range$0.68▼$2.84Volume1,884 shsAverage Volume85,697 shsMarket Capitalization$67.23 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Connect Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 623rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingConnect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageConnect Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently increased by 60.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently increased by 60.27%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Connect Biopharma this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTB Stock News HeadlinesCritical Survey: Connect Biopharma (NASDAQ:CNTB) & Talphera (NASDAQ:TLPH)October 20, 2024 | americanbankingnews.comAttovia Therapeutics Appoints Chief Financial OfficerOctober 15, 2024 | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)CNTB Stock Surges Over 5% Amid Strong Financial PerformanceOctober 2, 2024 | gurufocus.comCentessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia BSeptember 25, 2024 | seekingalpha.comSimcere Pharmaceutical Group Ltd (S2P.DU)September 25, 2024 | sg.finance.yahoo.comConnect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024September 10, 2024 | finance.yahoo.comConnect Biopharma Reports First Half 2024 Financial Results and Provides Business UpdateSeptember 5, 2024 | globenewswire.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $1.18 at the beginning of 2024. Since then, CNTB shares have increased by 3.4% and is now trading at $1.22. View the best growth stocks for 2024 here. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY). Company Calendar Today10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTB CUSIPN/A CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+555.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio12.04 Quick RatioN/A Sales & Book Value Annual Sales$24.12 million Price / Sales2.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.67Miscellaneous Outstanding Shares55,103,000Free Float42,767,000Market Cap$67.23 million OptionableOptionable Beta-0.35 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:CNTB) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.